Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 11:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 10,399 matching trials from the live ClinicalTrials.gov search.
Conditions
Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Limb Girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
Cooperative International Neuromuscular Research Group
Network
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Conditions
Primary Immune Deficiency
Interventions
IgPro20
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
2 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
Centennial, Colorado • North Palm Beach, Florida • Indianapolis, Indiana + 1 more
Conditions
Anemia, Sickle Cell
Interventions
ICL670, deferoxamine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
34
States / cities
Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
Completed Phase 1Phase 2 Interventional Results available

Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa

NCT01263379
Conditions
Epidermolysis Bullosa Dystrophica, Epidermolysis Bullosa
Interventions
LZRSE-Col7A1 Engineered Autologous Epidermal Sheets
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Redwood City, California
Conditions
Smith-Magenis Syndrome (SMS)
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 115 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Hereditary Hemochromatosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 100 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Congenital Anomaly, Pediatric Cancer
Interventions
Whole Genome Sequencing, Questionnaire Administration, Biospecimen collection, Laboratory Biomarker Analysis
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
0 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Patent Ductus Arteriosus (PDA)
Interventions
Device closure with AMPLATZER Duct Occluder, Objective Performance Criteria
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
6 Months to 18 Years
Enrollment
436 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
24
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 21 more
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Zidovudine, Didanosine, Ganciclovir
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Irvine, California • Washington D.C., District of Columbia • Galveston, Texas
Conditions
Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
Interventions
Biospecimen Collection
Other
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
25 Years to 65 Years
Enrollment
5 participants
Timeline
2023 – 2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Conditions
Erythropoietic Protoporphyria, EPP, X-Linked Protoporphyria, XLP, XLPP, X-Linked Dominant Erythropoietic Protoporphyria, XLEPP, XLDP
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
6
States / cities
Birmingham, Alabama • San Francisco, California • New York, New York + 3 more
Conditions
Spinal Muscular Atrophy 1
Interventions
Onasemnogene Abeparvovec-xioi
Biological
Lead sponsor
Novartis Gene Therapies
Industry
Eligibility
Not listed
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Congenital Heart Defects
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Orange, California
Conditions
Mild Autonomous Cortisol Secretion (MACS)
Interventions
Osilodrostat (Isturisa)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 4 Interventional Results available

Late-Onset Treatment Study Extension Protocol

NCT00455195
Conditions
Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD-II), Glycogenesis Type II, Acid Maltase Deficiency (AMD)
Interventions
alglucosidase alfa
Biological
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
8 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
26
States / cities
Anchorage, Alaska • Phoenix, Arizona • Beverly Hills, California + 23 more
Conditions
Chronic Rhinosinusitis (Diagnosis), Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 99 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 6 more
Conditions
Intercritical Gout
Interventions
Colchicine (Colcrys®), placebo, allopurinol
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
37
States / cities
Alabaster, Alabama • Mesa, Arizona • Upland, California + 34 more
Conditions
Epilepsy
Interventions
retigabine/ezogabine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 29 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
4
States / cities
Los Angeles, California • Wellington, Florida • Memphis, Tennessee + 1 more
Conditions
LMNA-Related Dilated Cardiomyopathy
Interventions
ARRY-371797, p38 inhibitor, oral
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Aurora, Colorado • Baltimore, Maryland • Boston, Massachusetts + 1 more
Conditions
Respiratory Distress Syndrome, Newborn, Pulmonary Surfactants, Intensive Care Units, Neonatal
Interventions
Echography-guided Surfactant THERapy (ESTHER)
Diagnostic Test
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
0 Hours to 2 Hours
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Hartford, Connecticut
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT03296345
Conditions
Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions
Ketamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oakland, California
Completed Not applicable Interventional

Post-operative Lite Run Study

NCT03135145
Conditions
Cerebral Palsy, Neurologic Disorder, Chromosome Abnormality, Spina Bifida
Interventions
Lite Run Gait Trainer, Usual Treatments
Device · Other
Lead sponsor
Gillette Children's Specialty Healthcare
Other
Eligibility
4 Years to 17 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Urologic Diseases, Male Urogenital Diseases, Penile Diseases, Corpus Callosum Malformation, Corpora Cavernosa; Inflammation, Trauma Injury
Interventions
Autologous tissue engineered corpora
Biological
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 60 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Winston-Salem, North Carolina